Data Monitoring in Clinical Trials
Monitoring of clinical trials for early evidence of benefit and harm has
gotten considerable attention.¹ More formal guidelines and requirements²⁻⁴
have evolved in recent years, but in fact monitoring of trials is a practice that
has been going on for almost four decades.⁵ For trials that involved conditions
or interventions with serious risks, such as mortality or major morbidity, the
tradition and policy has been to have an independent monitoring committee
to review accumulating data for evidence of harm or convincing benefit that
would require modifying or terminating a trial early. During the past four
decades, many trials have had monitoring committees to assume this respon-
sibility. With the new emphasis on monitoring, this type of activity is increas-
ing dramatically as the number of clinical trials being conducted to evaluate
new interventions for patients or participants with serious risk or serious out-
comes also increases. For example, policies of the National Institutes of Health
(NIH) in the United States (US) call for monitoring committees for all phase
III trials.² Guidelines of the US Food and Drug Administration suggest such
committees for trials of high-risk interventions or patients at high risk.³

As the number of monitoring committees increases, the challenge exists
to pass along the experiences and best practices of the monitoring process
to colleagues who are assuming this responsibility for the first time.
Textbooks such as the one by Ellenberg, Fleming, and DeMets⁶ provide many
of the basic principles for monitoring committees. Other texts such as those
by Friedman, Furberg, and DeMets;⁷ Meinert;⁸ Pocock;⁹ Jennison and
Turnbull;¹⁰ and Piantidosi¹¹ provide statistical fundamentals and methods for
the design, monitoring, and analysis of clinical trials. This text is intended
to complement those texts by providing a collection of examples or case
studies of monitoring experiences from a variety of trials across different
disease disciplines. Each case study will describe the background of the indi-
vidual trial, summarize the overall results, review the critical issues that
emerged in the monitoring of the trial, and finally reflect on the lessons
learned from that trial. All of the examples presented share the complexity
of the process of monitoring and the lesson that no single rule or algorithm
can replace the wisdom and judgment of a monitoring committee. Through
these examples, we hope to share the experience of these past committees
and pass along some of their sometimes hard-earned wisdom.

Selection of the case studies was largely based on the collective experi-
ences of the editors and their interactions with colleagues involved with clin-
ical trials. Many of the 29 examples are from the field of cardiology, where the practice of monitoring committees was established early. However, there are examples from other disciplines. Regardless of the disease, many of the lessons learned and practices are useful for any trial. Individual colleagues were invited to present the monitoring experience of a trial they were involved with as they saw it and experienced it. Their presentations and discussions do not necessarily represent the official view of either the trial sponsor, the trial investigators, or the trial monitoring committee. We have tried to get representation from each of these constituencies on many of the trials when possible.

For most of the past four decades, the existence and practice of monitoring committees has not been widely recognized or understood. Our belief is that clinical research will benefit with better understanding of the process by both the research community and the interested public. The intended audience for this book are those who are planning to serve on a monitoring committee or are already on one and wish to gain further insight into the monitoring and decision-making process. We also believe that these examples will be useful to investigators as they design their trials and propose monitoring procedures; to sponsors, who typically receive monitoring committee recommendations, and to regulatory agencies, who often must review the results of trials that have been monitored by a committee. In addition, Institutional Review Boards may benefit from these case studies since they ultimately have responsibility for protecting participants at the local level but must rely on the monitoring committee process for most multicenter trials and increasingly for institutional trials. Journal editors, sciences writers, and practicing physicians may also find these case studies instructive.

Over the past four decades, many individuals have served on monitoring committees and participated in the monitoring of many challenging studies. We wish to thank all of those individuals who have contributed directly or indirectly to the practice of monitoring and from whose experience we all have benefitted. We have listed in Appendix 1 the individuals who have served on the committees for the trials presented as case studies in this book and wish to thank them in particular.

ACKNOWLEDGMENTS

We also want to thank the many contributors to the drafting of these case studies. We have listed them in the section which follows. They contributed their experiences because of their commitment to clinical trials, the monitoring process, and to teaching the next generation of clinical trial researchers about the important process of monitoring trials for early evi-
dence of benefit or harm. We are grateful that they accepted our invitation and persevered through the drafts and editing process.

We would also like to acknowledge the substantial contributions by Ms. Suzanne Parman for her editorial and logistical support. Without her dedication this text could not have been completed in a timely fashion.

David L. DeMets
Curt D. Furberg
Lawrence M. Friedman

REFERENCES
Contributors

Susan Anderson
Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin
Data Monitoring in the Prospective Randomized Milrinone Survival Evaluation: Dealing with an Agonizing Trend

Alex Bajamonde
Genentech Inc., San Francisco, California
Making Independence Work: Monitoring the Bevacizumab Colorectal Cancer Clinical Trial

Jean-Pierre Boissel
Clinical Pharmacology Department, Claude Bernard University, Lyon, France
Stopping the Randomized Aldactone Evaluation Study Early for Efficacy

Byron W. Brown, Jr.
Stanford, California
The Nocturnal Oxygen Therapy Trial Data Monitoring Experience: Problem with Reporting Lags

Julie Buring
Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School; Boston, Massachusetts
Stopping the Carotene and Retinol Efficacy Trial: The Viewpoint of the Safety and Endpoint Monitoring Committee

Paul L. Canner
Maryland Medical Research Institute, Baltimore, Maryland
Breaking New Ground: Data Monitoring in the Coronary Drug Project

Heidi Christ-Schmidt
Statistics Collaborative, Washington, D.C.
Making Independence Work: Monitoring the Bevacizumab Colorectal Cancer Clinical Trial
Contributors

Charles Clark
Departments of Medicine, Pharmacology and Toxicology, School of Medicine, Indiana University, Bloomington, Indiana
Early Termination of the Diabetes Control and Complications Trial

Patricia Cleary
The Biostatistics Center, The George Washington University, Rockville, Maryland
Early Termination of the Diabetes Control and Complications Trial

Robert Cody
Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, Michigan
Data Monitoring in the Prospective Randomized Milrinone Survival Evaluation: Dealing with an Agonizing Trend

Theodore Colton
Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts
Challenges in Monitoring the Breast Cancer Prevention Trial

Joseph P. Costantino
Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania
Challenges in Monitoring the Breast Cancer Prevention Trial

Oscar Crofford
Department of Medicine, Vanderbilt University, Nashville, Tennessee
Early Termination of the Diabetes Control and Complications Trial

Jeffrey A. Cutler
National Heart, Lung, and Blood Institute, Division of Epidemiology and Clinical Applications, National Institutes of Health, Bethesda, Maryland
Data Monitoring in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Early Termination of the Doxazosin Treatment Arm

Barry R. Davis
The University of Texas Health Science Center at Houston, School of Public Health, Houston, Texas
Data Monitoring in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Early Termination of the Doxazosin Treatment Arm
David L. DeMets
Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin

*Data and Safety Monitoring in the Beta-Blocker Heart Attack Trial: Early Experience in Formal Monitoring Methods*

*Data Monitoring for the Aspirin Component of the Physicians’ Health Study: Issues in Early Termination for a Major Secondary Endpoint*

*The Data Monitoring Experience in the Cardiac Arrhythmia Suppression Trial: The Need To Be Prepared Early*

*The Nocturnal Oxygen Therapy Trial Data Monitoring Experience: Problem with Reporting Lags*

Kenneth Dickstein
Cardiology Division, Stavanger University Hospital, Stavanger, Norway

*Data Monitoring Experience in the Moxonidine Congestive Heart Failure Trial*

Fred Ederer
Bethesda, Maryland

*Assessing Possible Late Treatment Effects Early: The Diabetic Retinopathy Study Experience*

Susan S. Ellenberg
University of Pennsylvania School of Medicine, Center for Clinical Epidemiology and Biostatistics, Philadelphia, Pennsylvania

*FDA and Clinical Trial Data Monitoring Committees*

Frederick Ferris
Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland

*Early Termination of the Diabetes Control and Complications Trial*

Jan Feyzi
Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin

*Data Monitoring Experience in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure: Potentially High Risk Treatment in High Risk Patients*

Dianne M. Finkelstein
Biostatistics Center, Massachusetts General Hospital; Harvard Medical School, Boston, Massachusetts
Contributors

Data Monitoring Experience in the AIDS Clinical Trials Group Study #981: Conflicting Interim Results

Norman Fost
Departments of Pediatrics and Medical History and Bioethics, University of Wisconsin, Madison, Wisconsin
Monitoring a Clinical Trial with Waiver of Informed Consent: Diaspirin Cross-Linked Hemoglobin for Emergency Treatment of Post-Traumatic Shock

Gary Francis
Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio
Data Monitoring Experience in the Moxonidine Congestive Heart Failure Trial

Lawrence M. Friedman
Bethesda, Maryland
Data and Safety Monitoring in the Beta-Blocker Heart Attack Trial: Early Experience in Formal Monitoring Methods
The Data Monitoring Experience in the Cardiac Arrhythmia Suppression Trial: The Need To Be Prepared Early

Curt D. Furberg
Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Stopping the Randomized Aldactone Evaluation Study Early for Efficacy
Stopping a Trial for Futility: The Cooperative New Scandinavian Enalapril Survival Study II Trial
Lessons from Warfarin Trials in Atrial Fibrillation: Missing the Window of Opportunity

Saul Genuth
Division of Clinical and Molecular Endocrinology, Department of Medicine, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio
Early Termination of the Diabetes Control and Complications Trial

Stephen L. George
Department of Biostatistics and Bioinformatics, Director, Cancer Center Biostatistics, Duke University Medical Center, Durham, North Carolina
Controversies in the Early Reporting of a Clinical Trial in Early Breast Cancer
Deborah Grady  
Department of Epidemiology and Biostatistics, University of California, San Francisco, California  
*Consideration of Early Stopping and Other Challenges in Monitoring the Heart and Estrogen/progestin Replacement Study*

Mark R. Green  
Department of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina  
*Controversies in the Early Reporting of a Clinical Trial in Early Breast Cancer*

Robert J. Hardy  
Division of Biostatistics, The University of Texas Health Sciences Center at Houston, School of Public Health, Houston, Texas  
*Data and Safety Monitoring in the Beta-Blocker Heart Attack Trial: Early Experience in Formal Monitoring Methods*

David Harrington  
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts  
*Data Monitoring of a Placebo-Controlled Trial of Daclizumab in Acute Graft-Versus-Host Disease*

Robert G. Hart  
Department of Medicine (Neurology), University of Texas Health Science Center, San Antonio, Texas  
*Early Termination of the Stroke Prevention in Atrial Fibrillation I Trial: Protecting Participant Interests in the Face of Scientific Uncertainties and the Cruel Play of Chance*

Charles H. Hennekens  
University of Miami School of Medicine and Florida Atlantic University, Boca Raton, Florida  
*Data Monitoring for the Aspirin Component of the Physicians' Health Study: Issues in Early Termination for a Major Secondary Endpoint*  
*The Data Monitoring Experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Program*

Eric Holmgren  
Genentech Inc., South San Francisco, California
Contributors

Making Independence Work: Monitoring the Bevacizumab Colorectal Cancer Clinical Trial

Stephen B. Hulley
Department of Epidemiology & Biostatistics, University of California, San Francisco, California
Consideration of Early Stopping and Other Challenges in Monitoring the Heart and Estrogen/progestin Replacement Study

Mark A. Jacobson
Positive Health Program, Department of Medicine, University of California, San Francisco, California
Data Monitoring Experience in the AIDS Toxoplasmic Encephalitis Study

Desmond G. Julian
Emeritus Professor of Cardiology, University of Newcastle-upon-Tyne, London, England
Data Monitoring Experience in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure: Potentially High Risk Treatment in High Risk Patients
Stopping the Randomized Aldactone Evaluation Study Early for Efficacy
The Data Monitoring Experience in the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study: Hazards of Changing Primary Outcomes

Richard A. Kronmal
Department of Biostatistics, University of Washington, Seattle, Washington
Early Termination of the Stroke Prevention in Atrial Fibrillation I Trial: Protecting Participant Interests in the Face of Scientific Uncertainties and the Cruel Play of Chance

Henri Kulbertus
Cardiology Department, Centre Hospitalier Universitaire, Liege, Belgium
Stopping the Randomized Aldactone Evaluation Study Early for Efficacy

John M. Lachin
The Biostatistics Center, The George Washington University, Rockville, Maryland
Early Termination of the Diabetes Control and Complications Trial

Stephanie J. Lee
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Data Monitoring of a Placebo-Controlled Trial of Daclizumab in Acute Graft-Versus-Host Disease
Roger J. Lewis  
Department of Emergency Medicine, Harbor-UCLA Medical Center, Torrance, California, UCLA School of Medicine, Los Angeles, California and the Los Angeles Biomedical Research Institute, Torrance, California

*Monitoring a Clinical Trial with Waiver of Informed Consent: Diaspirin Cross-Linked Hemoglobin for Emergency Treatment of Post-Traumatic Shock*

Ruth McBride  
Axio Research Corporation, Seattle, Washington

*Early Termination of the Stroke Prevention in Atrial Fibrillation I Trial: Protecting Participant Interests in the Face of Scientific Uncertainties and the Cruel Play of Chance*

Anthony B. Miller  
Ontario, Canada

*Stopping the Carotene and Retinol Efficacy Trial: The Viewpoint of the Safety and Endpoint Monitoring Committee*

David Nathan  
Department of Medicine, Harvard University, Boston, Massachusetts

*Early Termination of the Diabetes Control and Complications Trial*

James D. Neaton  
Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota

*Data Monitoring Experience in the AIDS Toxoplasmic Encephalitis Study*

Milton Packer  
Center for Biostatistics and Clinical Science, University of Texas Southwestern Medical Center, Dallas, Texas

*Data Monitoring in the Prospective Randomized Milrinone Survival Evaluation: Dealing with an Agonizing Trend*

Lesly A. Pearce  
Biostatistical Consultant, Minot, North Dakota

*Early Termination of the Stroke Prevention in Atrial Fibrillation I Trial: Protecting Participant Interests in the Face of Scientific Uncertainties and the Cruel Play of Chance*

Stuart Pocock  
Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom
Contributors

Stopping the Randomized Aldactone Evaluation Study Early for Efficacy
The Data Monitoring Experience in the Candesartan in Heart Failure
Assessment of Reduction in Mortality and Morbidity Program
Data Monitoring Experience in the Moxonidine Congestive Heart Failure
Trial

Janice Pogue
Department of Medicine and Population Health Research Institute, Hamilton
Health Sciences and McMaster University, Hamilton, Ontario, Canada
Data Monitoring in the Heart Outcomes Prevention Evaluation and the
Clopitdogrel in Unstable Angina to Prevent Recurrent Ischemic Events
Trials: Avoiding Important Information Loss
Data Monitoring in the Randomized Evaluation of Strategies for Left
Ventricular Dysfunction Pilot Study: When Reasonable People Disagree

Carol K. Redmond
Department of Biostatistics, Graduate School of Public Health, University of
Pittsburgh, Pittsburgh, Pennsylvania
Challenges in Monitoring the Breast Cancer Prevention Trial

David Sackett
Trout Research and Education Centre at Irish Lake, Markdale, Ontario, Canada
Data Monitoring in the Heart Outcomes Prevention Evaluation and the
Clopitdogrel in Unstable Angina to Prevent Recurrent Ischemic Events
Trials: Avoiding Important Information Loss

Richard Schwarz
CV Ventures, LLC, Blue Bell, Pennsylvania
Data Monitoring in the Prospective Randomized Milrinone Survival
Evaluation: Dealing with an Agonizing Trend

Carolyn Siebert
Scotland, Maryland
Early Termination of the Diabetes Control and Complications Trial

Jay P. Siegel
Cenocor Research and Development, Inc., Malvern, Pennsylvania
FDA and Clinical Trial Data Monitoring Committees

Steven Snapinn
Amgen Inc., Thousand Oaks, California
Stopping a Trial for Futility: The Cooperative New Scandinavian Enalapril
Survival Study II
Charles H. Tegeler
Department of Neurology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Lessons from Warfarin Trials in Atrial Fibrillation: Missing the Window of Opportunity

Eric Vittinghoff
Department of Epidemiology and Biostatistics, University of California, San Francisco, California
Consideration of Early Stopping and Other Challenges in Monitoring the Heart and Estrogen/progestin Replacement Study

Duolao Wang
Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom
The Data Monitoring Experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Program

Hans Wedel
Epidemiology and Biostatistics, Nordic School of Public Health, Göteborg, Sweden
Data Monitoring Experience in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure: Potentially High Risk Treatment in High Risk Patients

Deborah N. Wentworth
Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota
Data Monitoring Experience in the AIDS Toxoplasmic Encephalitis Study

Richard J. Whitley
Pediatrics, Microbiology, Medicine and Neurosurgery, University of Alabama at Birmingham, Alabama
Clinical Trials of Herpes Simplex Encephalitis: The Role of the Data Monitoring Committee

John Wikstrand
Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital, Göteborg; and Clinical Science, Astra Zeneca R&D, Mölndal, Sweden
Data Monitoring Experience in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure: Potentially High Risk Treatment in High Risk Patients
Contributors

Lars Wilhelmsen
Section of Cardiology, The Cardiovascular Institute, Göteborg University, Sweden
The Data Monitoring Experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Program
Data Monitoring Experience in the Moxonidine Congestive Heart Failure Trial

George W. Williams
Amgen Inc., Thousand Oaks, California
The Nocturnal Oxygen Therapy Trial Data Monitoring Experience: Problem with Reporting Lags

O. Dale Williams
Division of Preventive Medicine, Department of Medicine, University of Alabama, Birmingham, Alabama
Stopping the Carotene and Retinol Efficacy Trial: The Viewpoint of the Safety and Endpoint Monitoring Committee
Consideration of EarlyStopping and Other Challenges in Monitoring the Heart and Estrogen/progestin Replacement Study

Janet Wittes
Statistics Collaborative, Washington, D.C.
Stopping the Randomized Aldactone Evaluation Study Early for Efficacy
Data Monitoring Experience in the Moxonidine Congestive Heart Failure Trial
Making Independence Work: Monitoring the Bevacizumab Colorectal Cancer Clinical Trial

D.G. Wyse
Libin Cardiovascular Institute of Alberta, Calgary, Alberta, Canada
Data Monitoring in the Heart Outcomes Prevention Evaluation and the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events Trials: Avoiding Important Information Loss

Salim Yusuf
Department of Medicine and Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada
Data Monitoring in the Heart Outcomes Prevention Evaluation and the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events Trials: Avoiding Important Information Loss
Data Monitoring in the Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study: When Reasonable People Disagree

David Zahrieh
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts

Data Monitoring of a Placebo-Controlled Trial of Daclizumab in Acute Graft-Versus-Host Disease
# Contents

Preface v
Contributors ix

## Section 1: Introduction/Overview

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Monitoring Committees: Why and How</td>
<td>David L. DeMets, Curt D. Furberg, Lawrence M. Friedman</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>Lessons Learned</td>
<td>David L. DeMets, Curt D. Furberg, Lawrence M. Friedman</td>
<td>14</td>
</tr>
<tr>
<td>3</td>
<td>FDA and Clinical Trial Data Monitoring Committees</td>
<td>Susan S. Ellenberg, Jay P. Siegel</td>
<td>39</td>
</tr>
</tbody>
</table>

## Section 2: General Benefit

<table>
<thead>
<tr>
<th>Case</th>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Assessing Possible Late Treatment Effects Early: The Diabetic Retinopathy Study Experience</td>
<td>Fred Ederer</td>
<td>55</td>
</tr>
<tr>
<td>2</td>
<td>Data and Safety Monitoring in the Beta-Blocker Heart Attack Trial: Early Experience in Formal Monitoring Methods</td>
<td>Lawrence M. Friedman, David L. DeMets, Robert Hardy</td>
<td>64</td>
</tr>
</tbody>
</table>

xxi
Case 3  Data Monitoring for the Aspirin Component of the Physicians' Health Study: Issues in Early Termination for a Major Secondary Endpoint  
David L. DeMets  
Charles H. Hennekens  
73

Case 4  Early Termination of the Stroke Prevention in Atrial Fibrillation I Trial: Protecting Participant Interests in the Face of Scientific Uncertainties and the Cruel Play of Chance  
Robert G. Hart  
Lesly A. Pearce  
Ruth McBride  
Richard A. Kronmal  
85

Case 5  Early Termination of the Diabetes Control and Complications Trial  
John M. Lachin  
Patricia Cleary  
Oscar Crofford  
Saul Genuth  
David Nathan  
Charles Clark  
Frederick Ferris  
Carolyn Siebert  
for the DCCT Research Group  
93

Case 6  Data Monitoring in the AIDS Clinical Trials Group Study #981: Conflicting Interim Results  
Dianne M. Finkelstein  
109

Case 7  Challenges in Monitoring the Breast Cancer Prevention Trial  
Carol K. Redmond  
Joseph P. Costantino  
Theodore Colton  
118

Case 8  Data Monitoring Experience in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure: Potentially High-Risk Treatment in High-Risk Patients  
Jan Feyzi  
Desmond Julian  
John Wikstrand  
Hans Wedel  
136
Case 9  Stopping the Randomized Aldactone Evaluation Study Early for Efficacy 148
Janet Wittes
Jean-Pierre Boissel
Curt D. Furberg
Desmond Julian
Henri Kulbertus
Stuart Pocock

Case 10  Data Monitoring in the Heart Outcomes Prevention Evaluation and the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events Trials: Avoiding Important Information Loss 158
Janice Pogue
David Sackett
DG Wyse
Salim Yusuf

Case 11  The Data Monitoring Experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Program 166
Stuart Pocock
Duolao Wang
Lars Wilhelmsen
Charles H. Hennekens

Section 3: General Harm

Introduction to Case Studies Showing Harmful Effects of the Intervention 179
David L. DeMets
Curt D. Furberg
Lawrence M. Friedman

Case 12  Breaking New Ground: Data Monitoring in the Coronary Drug Project 183
Paul L. Canner

Case 13  The Data Monitoring Experience in the Cardiac Arrhythmia Suppression Trial: The Need To Be Prepared Early 198
David L. DeMets
Lawrence M. Friedman
Case 14  Data Monitoring in the Prospective Randomized Milrinone Survival Evaluation: Dealing with an Agonizing Trend 209
Susan Anderson
Robert Cody
Milton Packer
Richard Schwarz

Case 15  Stopping the Carotene and Retinol Efficacy Trial: The Viewpoint of the Safety and Endpoint Monitoring Committee 220
Anthony B. Miller
Julie Buring
O. Dale Williams

Case 16  Monitoring a Clinical Trial With Waiver of Informed Consent: Diaspirin Cross-Linked Hemoglobin for Emergency Treatment of Post-Traumatic Shock 228
Roger J. Lewis
Norman Fost

Case 17  Consideration of Early Stopping and Other Challenges in Monitoring the Heart and Estrogen/Progestin Replacement Study 236
Stephen B. Hulley
Deborah Grady
Eric Vittinghoff
O. Dale Williams

Case 18  Data Monitoring in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Early Termination of the Doxazosin Treatment Arm 248
Barry R. Davis
Jeffrey A. Cutler

Case 19  Data Monitoring Experience in the Moxonidine Congestive Heart Failure Trial 260
Stuart Pocock
Lars Wilhelmsen
Kenneth Dickstein
Gary Francis
Janet Wittes
Case 20  Data Monitoring of a Placebo-Controlled Trial of Daclizumab in Acute Graft-Versus-Host Disease  
David Zahrieh  
Stephanie J. Lee  
David Harrington

Section 4: Special Issues

Introduction to Case Studies With Special Issues  
David L. DeMets  
Curt D. Furberg  
Lawrence M. Friedman

Case 21  Clinical Trials of Herpes Simplex Encephalitis: The Role of the Data Monitoring Committee  
Richard J. Whitley

Case 22  The Nocturnal Oxygen Therapy Trial Data Monitoring Experience: Problem With Reporting Lags  
David L. DeMets  
George W. Williams  
Byron W. Brown, Jr.

Case 23  Stopping a Trial for Futility: The Cooperative New Scandinavian Enalapril Survival Study II  
Steven Snapinn  
Curt D. Furberg

Case 24  Lessons From Warfarin Trials in Atrial Fibrillation: Missing the Window of Opportunity  
Charles H. Tegeler  
Curt D. Furberg

Case 25  Data Monitoring Experience in the AIDS Toxoplasmic Encephalitis Study  
James D. Neaton  
Deborah N. Wentworth  
Mark A. Jacobson
Contents

Case 26  Data Monitoring in the Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study: When Reasonable People Disagree 330

Janice Pogue
Salim Yusuf

Case 27  The Data Monitoring Experience in the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study: Hazards of Changing Primary Outcomes 337

Desmond Julian

Case 28  Controversies in the Early Reporting of a Clinical Trial in Early Breast Cancer 346

Stephen L. George
Mark R. Green

Case 29  Making Independence Work: Monitoring the Bevacizumab Colorectal Cancer Clinical Trial 360

Janet Wittes
Eric Holmgren
Heidi Christ-Schmidt
Alex Bajamonde

Appendix 1  Data Monitoring Committee Members 368

Appendix 2  Case Study Acronym Key (Title) 371

Index 372
SECTION 1

Introduction/Overview
MONITORING COMMITTEES: WHY AND HOW

David L. DeMets
Curt D. Furberg
Lawrence M. Friedman

INTRODUCTION

Monitoring of clinical trials encompasses many concepts. Among these concepts are oversight of trials to ensure that the protocol meets high standards, is feasible, ethical, and is being adhered to; that participant enrollment is satisfactory; that study procedures are being done properly; and that the data are of high quality and complete. Most importantly, however, monitoring is done to make certain, to the extent possible, that participants are not being unduly harmed, either directly by the intervention or indirectly by not receiving the current standard of care. Investigators cannot wait until the end of a clinical trial to examine the data and discover that a particular intervention was beneficial, when they could have made that discovery earlier, and taken appropriate action to help people receive the better treatment. Perhaps even more importantly, investigators cannot wait until the end of a trial to discover that a new treatment that was thought to be beneficial was, in fact, harmful. They must make those decisions as early as possible in order to save lives and preserve the health of the volunteer participants. This is a moral obligation of all who are involved in clinical trials. Once a decision to stop a study has been made, study participants expect, and have a right, to be informed of that decision in a timely manner.

The kind and amount of monitoring depend on the phase of the trial (early or late), organizational structure (single or multi-center), nature of the intervention (how safe it is known to be), whether the trial is open or blinded (sometimes termed “masked”), duration of the trial, and the types of participants being studied (how vulnerable they are thought to be). Many small, single-institution trials can be adequately monitored by Institutional Review Boards (IRBs) that rely on day-to-day oversight by investigators or other individuals tasked with the responsibility. Other trials, however, are best monitored by formally established committees, which provide input to IRBs. These committees go by a variety of names, including Data and Safety Monitoring...
Boards, Safety and Monitoring Efficacy Committees, and Data Monitoring Committees. These committees are commonly used for late-phase clinical outcome trials, which are typically multi-center; early-phase trials involving invasive or potentially dangerous interventions; and trials that enroll participants who are particularly vulnerable, such as children, extremely sick patients, and others incapable of providing true informed consent.

HISTORY

The concept of having committees monitor clinical trials goes back at least to the mid-1960s. Among the first trials using such a group was the Coronary Drug Project, or CDP\(^1\) (also see Case 12). The CDP, which began enrolling participants in 1965, was a clinical trial comparing five lipid-modifying drugs against placebo in 8,341 participants who had had a myocardial infarction. The trial included 53 clinical sites, a data coordinating center, and central laboratories, plus an administrative office at the then National Heart Institute of the National Institutes of Health (NIH). Because of the large size and many participating units, the CDP had a formal committee structure, which included a Steering Committee of selected investigators, to help manage the trial. Importantly, there was a Policy Board that oversaw the trial and advised the National Heart Institute. This group was composed of nationally respected scientists representing different fields of expertise who were not involved in the actual trial. As stated in the CDP protocol (see reference 1 for a summary of the protocol), the “Policy Board is to act in a senior advisory capacity to the Technical Group [the committee of all the investigators] in regard to policy questions on design, drug selection, ancillary studies, potential investigators and possible dropping of investigators whose performance is unsatisfactory.”

Because of uncertainty as to the best way of organizing and overseeing the CDP, the National Heart Institute, in 1967, commissioned a report, entitled, “Organization, Review, and Administration of Cooperative Studies.”\(^2\) This report is also known as the Greenberg Report, after the chairman of the committee that developed it, Bernard Greenberg. This report contained many recommendations, including several that are relevant to trial oversight and data monitoring:

A Policy Board or Advisory Committee of senior scientists, experts in the field of the study but not data-contributing participants in it, is almost essential.

A mechanism must be developed for early termination if unusual circumstances dictate that a cooperative study should not be continued.

Such action might be contemplated if the accumulated data answer the original question sooner than anticipated, if it is apparent that the study will not or cannot
achieve its stated aims, or if scientific advances since initiation render continuation superfluous. This is obviously a difficult decision that must be based on careful analysis of past progress and future expectation. If the National Heart Institute must initiate such action, it must do so only with the advice and on the recommendation of consultants.

Until 1968, CDP investigators were informed of accumulating outcome data. But in April of that year, the Policy Board recommended that such data not be made available to the investigators. Consistent with recommendations from the Greenberg Report, it further recommended that a Safety Monitoring Committee be formed to review those data on a regular basis. If safety issues arose, they were to be referred to the Policy Board, which considered them and made recommendations to the National Heart Institute. Initially, the members of the Safety Monitoring Committee were staff of the National Heart Institute, data coordinating center staff, the chairman of the study Steering Committee, the director of the electrocardiogram reading center, and a statistician from outside the study. Others with relevant expertise from outside the study were added subsequently. Both the Safety Monitoring Committee and the Policy Board met regularly to review study progress and accumulating data, but the Safety Monitoring Committee performed a more in-depth review of the data. It made recommendations to the Policy Board with regard to protocol changes or safety concerns.3

The Greenberg Report was extremely influential, in that, essentially, all future cooperative clinical trials funded by the National Heart Institute and its successor incarnations incorporated the idea of a separate committee that reviewed outcome data and made recommendations with regard to trial continuation or modification.

Although the details varied among institutes, other NIH institutes then developed monitoring systems over the years. Indeed, the concept of having an external, independent data-monitoring committee spread to clinical trials supported by industry and internationally. The NIH and the U.S. Food and Drug Administration have also developed guidelines for use of such committees.4,5

**STRUCTURE AND OPERATIONS OF MONITORING COMMITTEES**

Usually, voting members of monitoring committees are independent of the study investigators and sponsor. That is, no one who is involved with either the conduct of the trial or its funding and management should serve as a voting member on the committee. The committee may need to make recommendations that go against the interests of investigators and sponsors. These recommendations may range from dropping poor-performing centers, to alerting participants about safety concerns, to stopping the trial because
of adverse events. Investigators and sponsors who have financial or intellectual interests in particular outcomes have a potential conflict of interest and should not make such recommendations or be involved in the deliberations. How uninvolved a member needs to be is a matter of judgment. Can a member be from the same academic department as an investigator? Can they be from the same university? Is it appropriate for a member to be from the same organization as the sponsor, but in a different office or division from the one managing the trial? As a general rule, the more distant and independent, the better. But complete independence should not come at the expense of needed expertise. If the best person to serve on the committee is from the same university as one of the investigators, then that could outweigh concerns over potential or perceived conflicts of interest. In such cases, there needs to be sufficient care to ensure there are no real and important conflicts of interest on the part of the member and to minimize perceived conflicts.

The issue of conflict of interest applies to more than just the organization to which the committee member belongs; it also applies to financial holdings of the member and to future potential profits through holding of patents. All prospective members must be willing to disclose publicly, on an ongoing basis, their financial holdings and consulting or other relationships with companies that manufacture the drug, device, or biological being tested or with companies that manufacture direct competitor products. Having such holdings or relationships would not automatically exclude someone from serving on a monitoring committee, but there needs to be an open assessment of these potential conflicts and their magnitude. If conflicts do exist, it would be inappropriate for the member to vote on issues that relate specifically to that conflict.

What sorts of people should serve on a monitoring committee? The needed expertise is of several kinds. First, one or more experts in the scientific field of inquiry, including knowledge about the intervention, are necessary. Also essential are one or two experts in clinical trial design and biostatistics. Beyond that, monitoring committees often have bioethicists and/or patient advocates, especially for NIH-sponsored trials. Above all, at least some of the members should have served before on a monitoring committee. Experience in that activity is invaluable.

Others who may attend portions of meetings of the monitoring committee, but who are not formal, voting members, include senior investigators, representatives of the sponsor, and, although uncommon, someone from a drug (and device) regulatory agency. Attendance by someone from a regulatory agency can become complicated when the trial is multinational.

Monitoring committee meetings are typically divided into open, closed, and executive sessions. During the open session, no blinded outcome data
are disclosed or discussed (even if the trial itself is open, or unblinded). Rather, administrative issues, study progress, problems in participant enrollment, baseline data, participant adherence, and other similar matters are discussed, with a study investigator present to answer any questions. Unblinded outcome data, by study group, are presented and discussed during the closed session. Usually, attendance at this session is restricted to committee members and a study biostatistician who presents the data. It is generally accepted that if the sponsor is a drug or device company, attendance by that representative at the closed session is not a good idea. An exception would be if the study biostatistician is an employee of the company. In this case, however, rules as to what the statistician is and is not allowed to communicate to the sponsor must be established in advance. If the sponsor is a government agency with no commercial interests in the trial outcome, such as the National Institutes of Health or the Department of Veterans Affairs in the United States, some have argued that attendance is permissible, whereas others think that the same rules as apply to industry-sponsored studies should pertain. There is also disagreement as to whether the biostatistician presenting the data should be part of the investigator group, part of the study data analysis group but separate from the daily study management activities, or completely independent of the investigators. This chapter will not review the reasons for these differing views, but simply recognize that they exist.

Finally, there may be an executive session, where only the voting members of the committee and perhaps an executive secretary are present. This session allows the members to discuss issues more freely. If there are no contentious problems, however, the executive session may be unnecessary. The committee members can decide that at the time of the meeting.

There are two general models for monitoring committees. In the first, a committee is specifically established to monitor an individual trial. This is usually done when the trial is large and likely to go on for several years. In the second, a committee will monitor more than one trial. This is common in the case of networks of investigators that develop and conduct several or even many related protocols, such as for cancer and AIDS trials, and for IRB-appointed institution-wide monitoring committees. The advantages of the former are that the monitoring committee members have expertise in precisely the area of study and they can devote sufficient time to monitoring that single study. The primary advantage of the latter is that it is more efficient to have one committee monitor multiple protocols.

The frequency with which monitoring committees meet is determined by what is necessary to ensure the safety of the participants. The nature of the condition being studied, the kind of intervention, and how rapidly new data accumulate all influence that frequency. Typically, committees that monitor long-term trials meet every six to twelve months or when a speci-
fied percentage of participants have been accrued or a specified number of events have occurred. In addition, the option to review safety data in between, either in person or through telephone conference calls, should exist. Often, ongoing reports of individual adverse events are provided to the chairperson of the committee, who can decide whether or not to convene the full committee.

**MONITORING PROCESS**

It is not possible to foresee and prevent all harm. But the main purpose of monitoring is to make sure that no avoidable harm comes to the study participants as a result of being in the study. No study is risk free, but any potential harm must be counterbalanced or outweighed by potential benefits. To that end, the monitoring committee must be satisfied that the study is designed in as optimal a fashion as possible, with all reasonable safety precautions. After the study is underway, the committee regularly looks at accumulating data. In particular, it monitors study outcomes—both primary and secondary endpoints—and potential adverse events, including laboratory data, as appropriate. The committee must expect that unforeseen adverse events can and will occur, and must be prepared to modify its procedures to prevent or minimize the consequences of unexpected events.

In addition, because a study that is not well conducted cannot justifiably put participants at risk, the monitoring committee reviews study progress, in order to ensure the integrity of the trial. For example, is accrual of participants proceeding on schedule, and if not, how long will it take and will enough participants be entered eventually to address adequately the study hypotheses? Are study forms being completed and are the data of high quality? Are study procedures being done in a timely fashion? Are the analyses up-to-date? Are the participants taking the study medications as prescribed?

Monitoring committees must consider several principles. Various textbooks cover these in some detail, so we will only summarize them here.

First, of course, are ethical standards. The trial must begin in a position of clinical equipoise. That is, the informed scientific and medical communities do not know which of the approaches being tested in the trial is preferable. As the data begin to accumulate, the monitoring committee may decide that the trends in the primary outcome are so strong in one direction or another (i.e., in favor of or against the new intervention) that clinical equipoise is no longer tenable and the study must be stopped before its scheduled end. The study has achieved its goal of providing an answer. The sections that follow discuss many examples. Judgment, as well as science and statistics, enter into the decision. Connected with that is a balance of bene-